BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 31515284)

  • 1. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
    Lee TD; Lee OW; Brimacombe KR; Chen L; Guha R; Lusvarghi S; Tebase BG; Klumpp-Thomas C; Robey RW; Ambudkar SV; Shen M; Gottesman MM; Hall MD
    Mol Pharmacol; 2019 Nov; 96(5):629-640. PubMed ID: 31515284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding Site Interactions of Modulators of Breast Cancer Resistance Protein, Multidrug Resistance-Associated Protein 2, and P-Glycoprotein Activity.
    Deng F; Ghemtio L; Grazhdankin E; Wipf P; Xhaard H; Kidron H
    Mol Pharm; 2020 Jul; 17(7):2398-2410. PubMed ID: 32496785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissimilar Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Distribution of Erlotinib to the Retina and Brain in Humans and Mice.
    Biali ME; Auvity S; Cisternino S; Smirnova M; Hacker M; Zeitlinger M; Mairinger S; Tournier N; Bauer M; Langer O
    Mol Pharm; 2023 Nov; 20(11):5877-5887. PubMed ID: 37883694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of Human Brain Penetration of P-glycoprotein and Breast Cancer Resistance Protein Substrates Using In Vitro Transporter Studies and Animal Models.
    Feng B; Doran AC; Di L; West MA; Osgood SM; Mancuso JY; Shaffer CL; Tremaine L; Liras J
    J Pharm Sci; 2018 Aug; 107(8):2225-2235. PubMed ID: 29608887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening.
    Ye D; Harder A; Fang Z; Weinheimer M; Laplanche L; Mezler M
    Pharm Res; 2020 Sep; 37(10):194. PubMed ID: 32918191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2).
    Kannan P; Telu S; Shukla S; Ambudkar SV; Pike VW; Halldin C; Gottesman MM; Innis RB; Hall MD
    ACS Chem Neurosci; 2011 Feb; 2(2):82-9. PubMed ID: 22778859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.
    Shukla S; Robey RW; Bates SE; Ambudkar SV
    Drug Metab Dispos; 2009 Feb; 37(2):359-65. PubMed ID: 18971320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
    Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
    Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tetrahydrocannabinol and Its Major Metabolites Are Not (or Are Poor) Substrates or Inhibitors of Human P-Glycoprotein [ATP-Binding Cassette (ABC) B1] and Breast Cancer Resistance Protein (ABCG2).
    Chen X; Unadkat JD; Mao Q
    Drug Metab Dispos; 2021 Oct; 49(10):910-918. PubMed ID: 34326138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CC-115, a Dual Mammalian Target of Rapamycin/DNA-Dependent Protein Kinase Inhibitor in Clinical Trial, Is a Substrate of ATP-Binding Cassette G2, a Risk Factor for CC-115 Resistance.
    Beebe J; Zhang JT
    J Pharmacol Exp Ther; 2019 Nov; 371(2):320-326. PubMed ID: 31455631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo.
    De Vera AA; Gupta P; Lei Z; Liao D; Narayanan S; Teng Q; Reznik SE; Chen ZS
    Cancer Lett; 2019 Feb; 442():91-103. PubMed ID: 30391357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
    Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E
    Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening compounds with a novel high-throughput ABCB1-mediated efflux assay identifies drugs with known therapeutic targets at risk for multidrug resistance interference.
    Ansbro MR; Shukla S; Ambudkar SV; Yuspa SH; Li L
    PLoS One; 2013; 8(4):e60334. PubMed ID: 23593196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition.
    Zhou SF
    Xenobiotica; 2008 Jul; 38(7-8):802-32. PubMed ID: 18668431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on expression and function of P-gp/ABCB1 and BCRP/ABCG2 in the placenta and fetus.
    Han LW; Gao C; Mao Q
    Expert Opin Drug Metab Toxicol; 2018 Aug; 14(8):817-829. PubMed ID: 30010462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.
    Yang JJ; Milton MN; Yu S; Liao M; Liu N; Wu JT; Gan L; Balani SK; Lee FW; Prakash S; Xia CQ
    Drug Metab Lett; 2010 Dec; 4(4):201-12. PubMed ID: 20670210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational models for identifying potential P-glycoprotein substrates and inhibitors.
    Crivori P; Reinach B; Pezzetta D; Poggesi I
    Mol Pharm; 2006; 3(1):33-44. PubMed ID: 16686367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABCB1 Attenuates the Brain Penetration of the PARP Inhibitor AZD2461.
    de Gooijer MC; Buil LCM; Çitirikkaya CH; Hermans J; Beijnen JH; van Tellingen O
    Mol Pharm; 2018 Nov; 15(11):5236-5243. PubMed ID: 30252484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (18)F-FCWAY, a serotonin 1A receptor radioligand, is a substrate for efflux transport at the human blood-brain barrier.
    Liow JS; Zoghbi SS; Hu S; Hall MD; Hines CS; Shetty HU; Araneta MD; Page EM; Pike VW; Kreisl WC; Herscovitch P; Gottesman MM; Theodore WH; Innis RB
    Neuroimage; 2016 Sep; 138():134-140. PubMed ID: 27211474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxicity of cucurbitacin E from Citrullus colocynthis against multidrug-resistant cancer cells.
    Saeed MEM; Boulos JC; Elhaboub G; Rigano D; Saab A; Loizzo MR; Hassan LEA; Sugimoto Y; Piacente S; Tundis R; Yagi S; Khalid H; Efferth T
    Phytomedicine; 2019 Sep; 62():152945. PubMed ID: 31132750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.